Clinical Trial Update: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update assessing saruparib (AZD5305) plus camizestrant versus a CDK4/6 inhibitor plus endocrine therapy or camizestrant in HR-positive, H…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CDK4/6 inhibitor
• Camizestrant
• Saruparib (AZD5305) (saruparib)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Breast Cancer | Phase 3 | Status: RECRUITING